SEARCH

SEARCH BY CITATION

References

  • 1
    Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone. 2007; 40: 25164.
  • 2
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 33742.
  • 3
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 16576.
  • 4
    Nakamura I, Duong le T, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab. 2007; 25: 33744.
  • 5
    Rao H, Lu G, Kajiya H, Garcia-Palacios V, Kurihara N, Anderson J, Patrene K, Sheppard D, Blair HC, Windle JJ, Choi SJ, Roodman GD. Alpha9beta1: A novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res. 2006; 21: 165765.
  • 6
    Nakamura I, Gailit J, Sasaki T. Osteoclast integrin alphavbeta3 is present in the clear zone and contributes to cellular polarization. Cell Tissue Res. 1996; 286: 50715.
  • 7
    Zou W, Teitelbaum SL. Integrins, growth factors, and the osteoclast cytoskeleton. Ann N Y Acad Sci. 2010; 1192: 2731.
  • 8
    Nakamura I, Tanaka H, Rodan GA, Duong LT. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology. 1998; 139: 518293.
  • 9
    Gramoun A, Shorey S, Bashutski JD, Dixon SJ, Sims SM, Heersche JN, Manolson MF. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro. J Cell Biochem. 2007; 102: 34152.
  • 10
    van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Löwik C. Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. J Bone Miner Res. 1994; 9: 10218.
  • 11
    Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. C-fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest. 2003; 111: 74958.
  • 12
    McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000; 105: 43340.
  • 13
    Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev. 2005; 208: 88105.
  • 14
    Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol. 2005; 5: 54659.
  • 15
    Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by beta3 integrin. J Cell Biol. 2003; 162: 499509.
  • 16
    Faccio R, Grano M, Colucci S, Villa A, Giannelli G, Quaranta V, Zallone A. Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci. 2002 Jul 15; 115(Pt 14): 291929.
  • 17
    Elsegood CL, Zhuo Y, Wesolowski GA, Hamilton JA, Rodan GA. Duong le T. M-csf induces the stable interaction of cfms with alphavbeta3 integrin in osteoclasts. Int J Biochem Cell Biol. 2006; 38: 151829.
  • 18
    Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002; 110: 59911.
  • 19
    Jung YK, Jin JS, Jeong JH, Kim HN, Park NR, Choi JY. DICAM, a novel dual immunoglobulin domain containing cell adhesion molecule interacts with alphavbeta3 integrin. J Cell Physiol. 2008; 216: 60314.
  • 20
    Park H, Jung YK, Park OJ, Lee YJ, Choi JY, Choi Y. Interaction of fas ligand and fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol. 2005; 175: 7193201.
  • 21
    Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun. 2009; 378: 6459.
  • 22
    Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem. 2002; 277: 4736672.
  • 23
    Gingery A, Bradley E, Shaw A, Oursler MJ. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem. 2003; 89: 16579.
  • 24
    Kim HH, Chung WJ, Lee SW, Chung PJ, You JW, Kwon HJ, Tanaka S, Lee ZH. Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. Exp Cell Res. 2003; 289: 36877.
  • 25
    Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci. 1999; 112(Pt 22): 398593.
  • 26
    Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007; 176: 87788.
  • 27
    Crotti TN, Sharma SM, Fleming JD, Flannery MR, Ostrowski MC, Goldring SR, McHugh KP. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol. 2008; 215: 63644.
  • 28
    Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene. 2006; 372: 92102.
  • 29
    Song J, Li J, Qiao J, Jain S, Mark Evers B, Chung DH. PKD prevents H2O2-induced apoptosis via NF-kappaB and p38 MAPK in RIE-1 cells. Biochem Biophys Res Commun. 2009; 378: 6104.
  • 30
    Ivison SM, Graham NR, Bernales CQ, et al. Protein kinase D interaction with TLR5 is required for inflammatory signaling in response to bacterial flagellin. J Immunol. 2007; 178: 573543.
  • 31
    Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005; 5: 5163.
  • 32
    Smeeton J, Zhang X, Bulus N, Mernaugh G, Lange A, Karner CM, Carroll TJ, Fässler R, Pozzi A, Rosenblum ND, Zent R. Integrin-linked kinase regulates p38 MAPK-dependent cell cycle arrest in ureteric bud development. Development. 2010; 137: 323343.
  • 33
    Dossa T, Arabian A, Windle JJ, Dedhar S, Teitelbaum SL, Ross FP, Roodman GD, St-Arnaud R. Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem. 2011; 110: 9607.
  • 34
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3: 889901.
  • 35
    Sato K, Suematsu A, Nakashima T, Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K, Yamaguchi A, Takai T, Kodama T, Chatila TA, Bito H, Takayanagi H. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med. 2006; 12: 14106.
  • 36
    Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem. 2007; 282: 1824553.
  • 37
    Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun. 2006; 351: 99105.
  • 38
    Huang H, Ryu J, Ha J, Chang EJ, Kim HJ, Kim HM, Kitamura T, Lee ZH, Kim HH. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ. 2006; 13: 187991.